Investigators showed that topoisomerase 1 (TOP1) was highly expressed in neuroinflammatory conditions, and TOP1 inhibition using camptothecin and its FDA-approved analog topotecan reduced inflammatory responses in microglia/macrophages and ameliorated neuroinflammation in vivo.
[EMBO Reports]